Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4396 Comments
500 Likes
1
Latavion
Daily Reader
2 hours ago
I don’t know why but I feel late again.
👍 228
Reply
2
Dianaliz
Loyal User
5 hours ago
Could’ve acted sooner… sigh.
👍 38
Reply
3
Meylan
Power User
1 day ago
Anyone else late to this but still here?
👍 278
Reply
4
Garnieta
Experienced Member
1 day ago
I understood just enough to panic.
👍 120
Reply
5
Laylee
Influential Reader
2 days ago
This is straight-up wizard-level. 🧙♂️
👍 273
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.